"#1 Hospital in Washington UW Medical Center is Washington's only hospital nationally ranked in 6 specialties: cancer*, diabetes & endocrinology, ear, nose & throat, geriatrics, gynecology and rehabilitation. (*with Seattle Cancer Care Alliance)"

During the past decade, University of Washington Medical Center-Montlake conducted 73 clinical trials. In the 10-year time frame, 73 clinical trials started and 39 clinical trials were completed, i.e. on average, 53.4% percent of trials that started reached the finish line to date. In the past 5 years, 29 clinical trials started and 21 clinical trials were completed. i.e. 72.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Washington Medical Center-Montlake" #1 sponsor was "National Cancer Institute (NCI)" with 64 trials, followed by "SWOG Cancer Research Network" with 9 trials sponsored, "NRG Oncology" with 7 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 6 trials sponsored and "Alliance for Clinical Trials in Oncology" with 6 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Washington Medical Center-Montlake" #1 collaborator was "National Cancer Institute (NCI)" with 42 trials as a collaborator, "NRG Oncology" with 19 trials as a collaborator, "Canadian Cancer Trials Group" with 7 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator and "NCIC Clinical Trials Group" with 2 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "University of Washington Medical Center-Montlake" are "Fallopian Tube Transitional Cell Carcinoma" (8 trials), "Ovarian Seromucinous Carcinoma" (8 trials), "Recurrent Ovarian Carcinoma" (8 trials), "Fallopian Tube Clear Cell Adenocarcinoma" (7 trials) and "Fallopian Tube Endometrioid Adenocarcinoma" (7 trials). Many other conditions were trialed in "University of Washington Medical Center-Montlake" in a lesser frequency.

Most popular intervention types in "University of Washington Medical Center-Montlake" are "Drug" (88 trials), "Other" (81 trials), "Biological" (55 trials), "Procedure" (37 trials) and "Radiation" (27 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (51 trials), "Quality-of-Life Assessment" (34 trials), "Paclitaxel" (22 trials), "Computed Tomography" (20 trials) and "Questionnaire Administration" (19 trials). Other intervention names were less common.

The vast majority of trials in "University of Washington Medical Center-Montlake" are 93 trials for "All" genders, 30 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "University of Washington Medical Center-Montlake". undefined are not yet recruiting, 34 are recruiting, 67 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in University of Washington Medical Center-Montlake, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in University of Washington Medical Center-Montlake, 11 "Phase 1" clinical trials were conducted, 48 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 8 trials that are defined as “Not Applicable".